RVTY Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Revvity (NYSE: RVTY)
›
Revvity (NYSE: RVTY) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 11,000 employees.
The shares were at 151.59 USD on 19 November 2026, up 63.7% over 52 weeks. Its 52-week range is 81.22 USD to 171.74 USD: the price is 11.7% below the high and 86.6% above the low.
At a market capitalisation of 16.92B USD, it trades at 67.4 times trailing earnings and 25.5 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, a premium of 93% for RVTY. It pays a dividend yielding 0.18% (it pays out 12% of its earnings), against a median of 0.77% among the dividend payers in that peer group.
Revvity reports return on equity of 3.3%, an operating margin of 16.7% and revenue up 4.3% year over year.
Its debt exceeds its cash by 2.17B USD, a debt-to-equity ratio of 0.47. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Buy; their mean price target of 171.40 USD is 13.1% above the current price. The next earnings report is expected on 1 February 2027.